Navigation Links
Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h)
Date:5/25/2010

i(s_account);s.linkTrackVars='prop5,eVar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='94836224';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.o2h.com">http://www.o2h.com.

About Heptares Therapeutics

Heptares is a drug discovery company focused on identifying novel drug candidates targeting validated G-protein-coupled receptors (GPCRs) in several disease areas. Based on its unique StaR(TM) technology platform, Heptares has built an integrated drug discovery capability and aims to progress promising candidates internally and through strategic alliances.

GPCRs are the single most important family of drug targets in the human body, but because of their inherent instability they are refractory to structural studies and biochemical screening. StaR technology enables the engineering of stabilised GPCRs, making them amenable to these vital drug discovery approaches. There are many clinically relevant GPCR targets across a wide range of therapeutic areas where discovery is advancing slowly and for which structural information, novel screening approaches and potential antibody therapeutics would greatly enhance progress.

Heptares was founded in 2007 and its StaR technology arose out of the pioneering work of Heptares' founding scientists at the MRC Laboratory of Molecular Biology (Cambridge, UK) and the National Institute for Medical Research (London, UK).

    For more information, see http://www.heptares.com

    Contact information:

    Dr. Ekta Ahuja
    
SOURCE O2h
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
2. Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets
3. Talecris Biotherapeutics to Present at the 2010 Citi Investment Research Global Health Care Conference
4. Trius Therapeutics Awarded U.S. Department of Defense Contract to Develop Novel Antibiotics
5. Abviva Announces Further Patent Issuance for Technology Used in Breast Cancer Diagnostics and Therapeutics
6. Fate Therapeutics Expands Scientific Advisory Board to Advance iPSC Technology and Stem Cell Modulator Pipeline
7. Nile Therapeutics Announces Exercise of Over-Allotment Option for Recent Public Offering
8. Fate Therapeutics Appoints Tom Novak, Ph.D., as Vice President of Research and Drug Discovery
9. Orexigen(R) Therapeutics to Speak at Ninth Annual JMP Securities Research Conference
10. Nile Therapeutics Completes Dose Escalation in Ongoing Phase II Study
11. Talecris Biotherapeutics to Present at the Bank of America Merrill Lynch Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 Report Details ... highest potential revenues Do you want to find ... you revenue predictions for those biological drugs from ... you find financial data, R&D trends, opportunities and ... sales forecasts to 2024 at overall world market, ...
(Date:9/30/2014)... Over the last decade, the laboratory filtration market is ... increased acceptance of new filtration technologies in end users ... also catalyzing the growth of laboratory filtration market. , ... at a strong CAGR during the forecast period of ... by 2019. The market is mainly driven by the ...
(Date:9/30/2014)...  RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" ... a Canadian Patent for Inhibition or Reversal of ... claims using thymosin beta 4, various fragments and ... purposes.  The patent will expire in 2021. ... ) RegeneRx is focused on ...
(Date:9/30/2014)... Switzerland (PRWEB) September 30, 2014 ... software solutions for drug discovery and related ... FUNGITECT consortium has chosen Genedata Selector as ... sequencing (NGS) data. FUNGITECT is a European ... invasive fungal diseases via individualized anti-fungal drug ...
Breaking Biology Technology:Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3
... announced that Ricky Takai, Ph.D., has joined the company ... the firm, Dr. Takai will become the leader of ... Takai brings his more than 20 years experience in ... the field of education to the company.Most recently, Dr. ...
... Inc. (Nasdaq: BMRN ) today announced ... placebo-controlled clinical study of 6R-BH4 in patients with ... no statistical significance observed between the 6R-BH4 treatment ... peak walking time (PWT), did not show a ...
... CHICAGO, Feb. 3 Advanced Life Sciences Holdings,Inc. (Nasdaq: ... the discovery,development and commercialization of novel drugs in the ... that the Company,will make a corporate presentation to investors ... Company,s presentation will be delivered in the Windsor Suite,at ...
Cached Biology Technology:Dr. Ricky Takai, Expert in Designing and Managing Federal Evaluation Studies in Education, Joins Abt Associates 2Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 2Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 3Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 4Advanced Life Sciences to Present at the 11th Annual BIO CEO & Investor Conference 2Advanced Life Sciences to Present at the 11th Annual BIO CEO & Investor Conference 3
(Date:10/1/2014)... October 1, 2014 Novel ... life science field  The life science ... go over the years. Some are shooting stars ... is a novel detection technology that has raised ... finally, this technology is becoming commercially available. With ...
(Date:9/30/2014)... something that we enjoy when we visit a national park ... of ourselves as a part of nature? A bird,s nest ... , The answers to these questions reflect different cultural ... and in cultural artifacts. , A new Northwestern University study, ... Center of Chicago and the Menominee tribe of Wisconsin, focuses ...
(Date:9/30/2014)... and Howard Hughes Medical Institute investigator, and Margarita ... in the 2014 round of grants from the ... (Brain Research through Advancing Innovative Neurotechnologies) Initiative for ... 30, provides more than $3 million in funding ... The BRAIN Initiative, launched last year, is a ...
Breaking Biology News(10 mins):First-of-a-kind Solution for Utilizing Photon Upconversion 2The cultural side of science communication 2Salk scientists receive $3 million for BRAIN Initiative grant 2
... than a dozen countries joined together to sequence the tomato ... The Tomato Genomics Consortium directed the research effort, which ... Foundation and the USDA,s Agriculture Research Services. The OU ... Emeritus in the College of Arts and Sciences, was one ...
... 2012) -- A detailed analysis of more than 4 ... help electricity producers slash as much as 30 percent ... dioxide from power plant emissions. The research by ... Lawrence Berkeley National Laboratory (LBNL) and the Electric Power ...
... Madrid, May, 31st, 2012.- Madrid will become ... during the Biomedical Innovation Conference 2012, focused on ... Madrid-MIT M+Vision Consortium. This new organization has been ... and the regional Government of the Comunidad de ...
Cached Biology News:New materials could slash energy costs for CO2 capture 2New materials could slash energy costs for CO2 capture 3MADRID-MIT M+Vision Consortium hosts Biomedical Innovation Conference 2012 2
BD Falcon Center-well 60 mm In Vitro Fertilization (IVF) Dish, nonembryotoxic, noncytotoxic, tissue-culture treated polystyrene. (20/sp, 500/ca) Packaging: 20 / sleeve, 500 / case ...
... Collagen I 60 mm Culture Dishes BD ... treated polystyrene with a uniform application of rat ... Collagen I ,Surface : ECM/attachment ... ,Dim nominal : 60 mm x ...
...
The piston kit includes 2 pistons to service one F10 pump of a BioLogic DuoFlow workstation....
Biology Products: